Evidence map›Paper›PMID 34664008›Full record

ArticleAnnual reviews in control2021

Modeling and control of epidemics through testing policies.

Muhammad Umar B Niazi, Alain Kibangou, Carlos Canudas-de-Wit, Denis Nikitin, Liudmila Tumash, Pierre-Alexandre Bliman

Abstract read
In one paragraph

Article in Annual reviews in control, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Muhammad Umar B NiaziUniv. Grenoble Alpes, CNRS, Inria, Grenoble INP, GIPSA-Lab, 38000 Grenoble, France.
Alain KibangouUniv. Grenoble Alpes, CNRS, Inria, Grenoble INP, GIPSA-Lab, 38000 Grenoble, France.
Carlos Canudas-de-WitUniv. Grenoble Alpes, CNRS, Inria, Grenoble INP, GIPSA-Lab, 38000 Grenoble, France.
Denis NikitinUniv. Grenoble Alpes, CNRS, Inria, Grenoble INP, GIPSA-Lab, 38000 Grenoble, France.
Liudmila TumashUniv. Grenoble Alpes, CNRS, Inria, Grenoble INP, GIPSA-Lab, 38000 Grenoble, France.
Pierre-Alexandre BlimanSorbonne Université, Université Paris-Diderot SPC, Inria, CNRS, Laboratoire Jacques-Louis Lions, équipe Mamba, 75005 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testing is a crucial control mechanism in the beginning phase of an epidemic when the vaccines are not yet available. It enables the public health authority to detect and isolate the infected cases from the population, thereby limiting the disease transmission to susceptible people. However, despite the significance of testing in epidemic control, the recent literature on the subject lacks a control-theoretic perspective. In this paper, an epidemic model is proposed that incorporates the testing rate as a control input and differentiates the undetected infected from the detected infected cases, who are assumed to be removed from the disease spreading process in the population. After estimating the model on the data corresponding to the beginning phase of COVID-19 in France, two testing policies are proposed: the so-called best-effort strategy for testing (BEST) and constant optimal strategy for testing (COST). The BEST policy is a suppression strategy that provides a minimum testing rate that stops the growth of the epidemic when implemented. The COST policy, on the other hand, is a mitigation strategy that provides an optimal value of testing rate minimizing the peak value of the infected population when the total stockpile of tests is limited. Both testing policies are evaluated by their impact on the number of active intensive care unit (ICU) cases and the cumulative number of deaths for the COVID-19 case of France.

Indexed as

Control policiesEpidemic modelingModel estimationTesting

Identifiers

PMID34664008
PMCPMC8514419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.